Donate

On the Horizon – CABOZANTINIB IN MEN WITH ADVANCED PROSTATE CANCER: RESULTS OF A PHASE II RANDOMIZED TRIAL

Cabozantinib (XL184) is an orally bioavailable tyrosine kinase inhibitor with activity against MET and vascular endothelial growth factor receptor 2. It is designed to target the men with castration resistant prostate cancer (CRPC). Results from a phase II randomized discontinuation trial with an expansion cohort of XL184 have recently been released. The trial included men [...]

On the Horizon: Cabozantinib (XL184) Phase II Trial in Men with Castrate Resistant Prostate Cancer

We are again looking at a potentially new block buster drug to treat men with advanced prostate cancer whose cancer has become castrate resistant. This potential drug seems to have clinical activity in both soft tissue and bone mets. This investigational drug is called Cabozantinib (XL184). It is a tyrosine kinase inhibitor with activity against [...]

ASCO 2011: Phase II Cabozantinib Trial in Patients with Advanced Solid Tumors and Bone Metastases

Data from the recent ASCO conference on a phase II study of cabozantinib (XL184) in patients with advanced solid tumors, including prostate cancer, demonstrates that the investigational treatment has activity in both bone and soft tissue. This study evaluated the efficacy and safety of cabozantinib compared to placebo in 9 different solid tumor types including [...]

Go to Top